Results 1 - 20 of 19,613 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Show only
- Peer-reviewed Journals (18,571)
Refined by:
subject:
Life Sciences & Biomedicine
| Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
|---|---|---|---|
| 1 |
Material Type: Article
|
|
CTLA-4: a moving target in immunotherapyBlood, 2018-01, Vol.131 (1), p.58-67 [Peer Reviewed Journal]2018 American Society of Hematology ;2018 by The American Society of Hematology. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2017-06-741033 ;PMID: 29118008Full text available |
| 2 |
Material Type: Article
|
|
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC TrialJournal of thoracic oncology, 2021-05, Vol.16 (5), p.860-867 [Peer Reviewed Journal]2021 International Association for the Study of Lung Cancer ;Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. ;ISSN: 1556-0864 ;EISSN: 1556-1380 ;DOI: 10.1016/j.jtho.2020.12.015 ;PMID: 33476803Full text available |
| 3 |
Material Type: Article
|
|
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON StudyJournal of clinical oncology, 2023-02, Vol.41 (6), p.1213-1227 [Peer Reviewed Journal]2022 by American Society of Clinical Oncology 2022 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.22.00975 ;PMID: 36327426Full text available |
| 4 |
Material Type: Article
|
|
B7-H3: An Attractive Target for Antibody-based ImmunotherapyClinical cancer research, 2021-03, Vol.27 (5), p.1227-1235 [Peer Reviewed Journal]2020 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-20-2584 ;PMID: 33051306Full text available |
| 5 |
Material Type: Article
|
|
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategiesBlood, 2018-01, Vol.131 (1), p.49-57 [Peer Reviewed Journal]2018 American Society of Hematology ;2018 by The American Society of Hematology. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2017-06-741041 ;PMID: 29118009Full text available |
| 6 |
Material Type: Article
|
|
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial CancerJournal of clinical oncology, 2023-01, Vol.41 (1), p.22-31 [Peer Reviewed Journal]2022 by American Society of Clinical Oncology 2022 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.22.01643 ;PMID: 36041086Full text available |
| 7 |
Material Type: Article
|
|
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodiesNature medicine, 2022-03, Vol.28 (3), p.490-495 [Peer Reviewed Journal]2022. The Author(s), under exclusive licence to Springer Nature America, Inc. ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2022. ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2022 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-021-01678-y ;PMID: 35046573Full text available |
| 8 |
Material Type: Article
|
|
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Journal of clinical oncology, 2017-12, Vol.35 (35), p.3924-3933 [Peer Reviewed Journal]2017 by American Society of Clinical Oncology 2017 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2017.74.3062 ;PMID: 29023213Full text available |
| 9 |
Material Type: Article
|
|
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and MemoryCell, 2019-04, Vol.177 (2), p.414-427.e13 [Peer Reviewed Journal]2019 The Authors ;Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2019.02.016 ;PMID: 30951669Full text available |
| 10 |
Material Type: Article
|
|
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscapeThe Lancet infectious diseases, 2023-01, Vol.23 (1), p.e2-e21 [Peer Reviewed Journal]2023 Elsevier Ltd ;Copyright © 2023 Elsevier Ltd. All rights reserved. ;2023. Elsevier Ltd ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(22)00291-2 ;PMID: 35952703Full text available |
| 11 |
Material Type: Article
|
|
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN studyNeurology, 2018-12, Vol.91 (24), p.e2211-e2221 [Peer Reviewed Journal]2018 American Academy of Neurology ;Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. ;Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 2018 American Academy of Neurology ;ISSN: 0028-3878 ;EISSN: 1526-632X ;DOI: 10.1212/WNL.0000000000006640 ;PMID: 30446596Full text available |
| 12 |
Material Type: Article
|
|
Antibody-drug conjugates--an emerging class of cancer treatmentBritish journal of cancer, 2016-02, Vol.114 (4), p.362-367 [Peer Reviewed Journal]Copyright Nature Publishing Group Feb 16, 2016 ;Copyright © 2016 Cancer Research UK 2016 Cancer Research UK ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2015.435 ;PMID: 26742008 ;CODEN: BJCAAIFull text available |
| 13 |
Material Type: Article
|
|
Next generation antibody drugs: pursuit of the 'high-hanging fruit'Nature reviews. Drug discovery, 2018-03, Vol.17 (3), p.197-223 [Peer Reviewed Journal]COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group Mar 2018 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2017.227 ;PMID: 29192287Full text available |
| 14 |
Material Type: Article
|
|
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet (British edition), 2017-12, Vol.390 (10111), p.2461-2471 [Peer Reviewed Journal]2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Dec 2, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)31827-5 ;PMID: 28993052Full text available |
| 15 |
Material Type: Article
|
|
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial CancerJournal of clinical oncology, 2019-10, Vol.37 (30), p.2786-2794 [Peer Reviewed Journal]2019 by American Society of Clinical Oncology 2019 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.19.01021 ;PMID: 31461377Full text available |
| 16 |
Material Type: Article
|
|
Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell, 2017-11, Vol.171 (4), p.934-949.e16 [Peer Reviewed Journal]2017 Elsevier Inc. ;Copyright © 2017 Elsevier Inc. All rights reserved. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2017.09.028 ;PMID: 29033130Full text available |
| 17 |
Material Type: Article
|
|
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of PsoriasisThe Journal of immunology (1950), 2018-09, Vol.201 (6), p.1605-1613 [Peer Reviewed Journal]Copyright © 2018 by The American Association of Immunologists, Inc. ;ISSN: 0022-1767 ;EISSN: 1550-6606 ;DOI: 10.4049/jimmunol.1800013 ;PMID: 30181299Full text available |
| 18 |
Material Type: Article
|
|
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialThe lancet oncology, 2016-11, Vol.17 (11), p.1558-1568 [Peer Reviewed Journal]Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Nov 01, 2016 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(16)30366-7 ;PMID: 27622997 ;CODEN: LANCAOFull text available |
| 19 |
Material Type: Article
|
|
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals of the rheumatic diseases, 2017-06, Vol.76 (6), p.960-977 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Copyright: 2017 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0003-4967 ;ISSN: 1468-2060 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2016-210715 ;PMID: 28264816 ;CODEN: ARDIAOFull text available |
| 20 |
Material Type: Article
|
|
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19New England Journal of Medicine, 2022-06, Vol.386 (23), p.2188-2200 [Peer Reviewed Journal]Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;2022. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2116620 ;PMID: 35443106Digital Resources/Online E-Resources |
Results 1 - 20 of 19,613 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Personalize your results
Refine Search Results
Expand My Results
Show only
- Peer-reviewed Journals (18,571)
Refine My Results
Creation Date
- Before 1989 (303)
- 1989 To 1996 (1,274)
- 1997 To 2004 (3,152)
- 2005 To 2013 (9,645)
- After 2013 (5,240)
-
More options
New Records
Resource Type
- Articles (19,602)
- Book Chapters (6)
- magazinearticle (4)
- Books (1)
-
More options
Subject
- Antibodies, Monoclonal - Therapeutic Use (19,604)
- Humans (17,905)
- Female (8,347)
- Male (7,116)
- Biological And Medical Sciences (6,203)
- Medical Sciences (5,871)
- Middle Aged (5,350)
- Animals (5,185)
- Oncology (5,048)
- Adult (4,657)
- Antibodies, Monoclonal, Humanized (4,447)
- Treatment Outcome (4,262)
- Aged (3,567)
- Immunology (3,266)
- Antineoplastic Agents - Therapeutic Use (3,150)
- Mice (3,024)
- Antibodies, Monoclonal - Adverse Effects (2,858)
- Pharmacology. Drug Treatments (2,625)
-
More options
Databases
- MEDLINE (19,609)
- ProQuest Central (8,996)
- Geneva Foundation Free Medical Journals at publisher websites (7,572)
- PubMed Central (5,008)
- HighWire Press (Free Journals) (4,210)
- DOAJ Directory of Open Access Journals (3,018)
- ROAD: Directory of Open Access Scholarly Resources (1,779)
- Open Access: Wiley-Blackwell Open Access Journals (1,566)
- Springer_OA刊 (1,118)
- ProQuest One Psychology (907)
- IngentaConnect Open Access (800)
- Nature Free (615)
- Taylor & Francis Open Access Journals (462)
- Free E- Journals (220)
- Freely Accessible Japanese Titles (ERDB Project) (218)
- Oxford Journals Open Access Collection (187)
- Journals@Ovid Open Access Journal Collection Rolling (180)
- BMJ Open Access Journals (177)
- Hyper Article en Ligne (HAL) (Open Access) (152)
- SWEPUB Freely available online (139)
-
More options
Language
Journal Title
- Annals Of Oncology (268)
- Annals Of The Rheumatic Diseases (491)
- Arthritis And Rheumatism (284)
- Blood (379)
- Cancer Research (260)
- Clinical Cancer Research (483)
- Journal Of Clinical Oncology (366)
- Rheumatology (289)
- The Journal Of Immunology (281)
- The New England Journal Of Medicine (436)
-
More options
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||